CDH24: A Promising Drug Target and Biomarker for Certain Cancers

Target Name: CDH24

NCBI ID: G64403

CDH24

CDH24: A Promising Drug Target and Biomarker for Certain Cancers

Introduction

Cadherins are a family of transmembrane proteins that play a crucial role in cell-cell adhesion. CDH24, a member of the cadherin family, has been identified as a potential drug target and biomarker for various cancers. This article will discuss the biology of CDH24, its functions in cancer progression, and the potential for targeting this protein in cancer treatment.

Biography of CDH24

CDH24 is a 24kDa transmembrane protein that belongs to the cadherin family. It is a key regulator of cell-cell adhesion and has been implicated in various physiological processes, including cell growth, differentiation, and angiogenesis. CDH24 is expressed in various tissues, including epithelial , mesenchymal, and neural cells.

CDH24 functions as a negative regulator of the Wnt/FGF signaling pathway. This pathway is involved in the development and maintenance of tissues and is critical for normal growth and development. CDH24 functions by inhibiting the activity of the transcription factor SMAD, which is a key regulator of the Wnt/FGF signaling pathway.

CDH24's functions in cancer progression

The role of CDH24 in cancer progression is well understood. It has been shown to be involved in the development and progression of various cancers, including breast, ovarian, and colorectal cancers.

In breast cancer, CDH24 has been shown to promote the growth and survival of cancer cells. It has also been implicated in the development of resistance to chemotherapy in breast cancer.

In ovarian cancer, CDH24 has been shown to contribute to the development and progression of ovarian epithelial cancer. It has also been linked to the poor prognosis of ovarian cancer.

In colorectal cancer, CDH24 has been shown to promote the growth and survival of cancer cells and has also been implicated in the development of resistance to chemotherapy in colorectal cancer.

CDH24 as a potential drug target

CDH24 is a potential drug target for various cancers due to its involvement in cancer progression. various signaling pathways, including the Wnt/FGF signaling pathway, can be targeted by small molecules.

One approach to targeting CDH24 is the use of small molecules that can inhibit the activity of SMAD, the transcription factor that regulates the Wnt/FGF signaling pathway.

Another approach is the use of monoclonal antibodies (MCAs), which are laboratory-produced antibodies that can selectively bind to CDH24 and target it for destruction. MCA-conjugated antibodies have been shown to be effective in targeting CDH24 and have the potential to be used in cancer treatment.

CDH24 as a biomarker

CDH24 has also been shown to be a potential biomarker for various cancers. Its expression has been shown to be associated with the progression of cancer and can be used as a diagnostic or predictive marker.

In breast cancer, CDH24 has been shown to be a positive predictor of the outcome of chemotherapy. Similarly, in ovarian cancer, CDH24 has been shown to be a positive predictor of the outcome of chemotherapy.

Conclusion

CDH24 is a key regulator of cell-cell adhesion and has been implicated in various physiological processes. Its functions in cancer progression make it a potential drug target and biomarker for various cancers. The use of small molecules and monoclonal antibodies to target CDH24 has the potential to revolutionize cancer treatment. Further research is needed to fully understand the role of CDH24 in cancer biology and its potential as a drug target and biomarker.

Protein Name: Cadherin 24

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Cadherin-24 mediate strong cell-cell adhesion

The "CDH24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets